There’s another PrEP player in the game, but they’re playing for the same team: Gilead Sciences, who now corner the market on HIV prevention pills.
In a press release to GayNrd, Gilead Sciences, the drug giant behind the blockbuster HIV prevention pill Truvada, states its won FDA approval today to market Descovy — a medication already used by those who have HIV — as its next-generation prevention drug.
Descovy is now approved for HIV PrEP in everyone except people who have vaginal sex, since its efficacy has not been studied in this population; for these patients, Truvada is an approved option.
Photo above: The HIV virus rendered in 3-D. Shutterstock.
“Descovy for PrEP provides a new HIV prevention option that matches Truvada’s high efficacy with statistically significant improvements in renal and bone safety, which can be an important consideration as people at risk increasingly use PrEP for longer periods of time,” Daniel O’Day, Gilead’s CEO, said in a statement.
Today, because of landmark biomedical and scientific research advances, there are unprecedented opportunities to significantly reduce new HIV infections,” said Edwin DeJesus, MD, FACP, FIDSA, Medical Director, Orlando Immunology Center. “Descovy for PrEP offers healthcare providers and appropriate people at risk for HIV an additional biomedical prevention option with a demonstrated improvement in bone and renal safety parameters as compared to Truvada.”
Descovy does not prevent other sexually transmitted infections or cure HIV infection or AIDS.